Search

Background: Acne confers an increased risk of physical, psychiatric, and psychosocial sequelae, potentially affecting multiple dimensions of health-related quality of life (HRQoL). Morbidity associated with truncal acne is poorly understood. Objective: To determine how severity and location of acne lesions impact the HRQoL of those who suffer from it. Methods: A total of 694 subjects with combined facial and truncal acne (F+T) and 615 with facial acne only (F) participated in an online, international survey. Participants self-graded the severity of their acne at different anatomical locations and completed the dermatology life quality index (DLQI). Results: The F+T participants were twice as likely to report “very large” to “extremely large” impact on HRQoL (ie, DLQI > 10 and children's DLQI [CDLQI] > 12) as compared with the F participants (DLQI: odds ratio [OR] 1.61 [95% confidence interval {CI} 1.02-2.54]; CDLQI: OR 1.86 [95% CI 1.10-3.14]). The impact of acne on HRQoL increased with increasing acne severity on the face (DLQI and CDLQI P values = .001 and .017, respectively), chest (P = .003; P = .008), and back (P = .001; P = .028). Limitations: Temporal evaluation of acne impact was not estimated. Conclusions: Facial and truncal acne was associated with a greater impact on HRQoL than facial acne alone. Increasing severity of truncal acne increases the adverse impact on HRQoL irrespective of the severity of facial acne.

The 4th Industrial Revolution (4.0 IR), fundamentally disrupts the technologies characterizing the first three industrial revolutions. In the nowadays global management phase (competitive globalisation), the business model based on excess supply (i.e., over-supply model, in which competitors face volatile production and progressively falling prices) is now inadequate for aggressive global corporate policies. Producing more and wasting less require today a new global business model based on the progressive disappearance of marginal global companies (oversize economy, characterized by lower production and sales costs, and by large company size). Standardized production has now fallen into a crisis that drives companies towards 4.0 technologies i.e., in the pursuit of new conditions of efficiency that are more open to innovation, towards productive flexibility, and even towards competitive imitation.

Copyright of Practical Pharmacy & Clinical Remedies is the property of Editorial Department of Practical Pharmacy & Clinical Remedies and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background Acne is a chronic skin disorder which generally presents in adolescence but continues into adulthood, and negatively affects both physical and psychosocial well-being. Presently, there are no validated acne-specific quality-of-life (QoL) measures that include dimensions for both facial and torso acne. Objective: The objective of this study was to develop a QoL instrument for both facial and torso acne (CompAQ) in accordance with recommended standards. Methods: A literature review and Delphi survey of patients and clinicians were used to develop the conceptual framework for outcomes perceived important to acne patients. An initial version of the measure was developed, CompAQ-v1, and pilot tested with patients via cognitive interviews. Results: The Delphi survey generated 4 domains (physical, psychological, sociological, and treatment) and 54 items. These, along with a literature review and input from clinical experts, informed the development of the CompAQ-v1. Eleven cognitive interviews were conducted, resulting in the second version of the measure, CompAQ-v2. Psychometric validation resulted in the final 20-item CompAQ measure comprising 5 domains. An abbreviated 5-item measure was also developed (CompAQ-SF). Conclusion: CompAQ and CompAQ-SF are instruments intended to evaluate QoL in patients with acne on their face or torso. The former is a 21-item QoL intended for research, while the latter is intended for clinical practice. [ABSTRACT FROM AUTHOR]

Background: Diabetes is a serious public health concern in China, with 30% of patients developing retinopathy, and diabetic macular edema (DME) having the biggest impact on vision. High blood glucose level can cause retinal cell hypoxia, thus promoting vascular endothelial growth factor (VEGF) formation and increasing vascular permeability, which induces DME. Moreover, cell hypoxia can accelerate the rate of apoptosis, which leads to the aging of patients. In severe cases, optic cell apoptosis or retinal fibrosis and permanent blindness may occur., Aim: To investigate and compare the efficacy, mechanism, and differences between two anti-VEGF drugs (Compaq and ranibizumab) in DME patients., Methods: Ninety-six patients with DME who attended our hospital from April 2018 to February 2020 were included and randomly divided into two groups (Compaq group and ranibizumab group). The groups received vitreal cavity injections of 0.5 mg Compaq and 0.5 mg ranibizumab, respectively, once a month. The best corrected visual acuity (BCVA), intraocular pressure (IOP), macular retinal thickness (CMT), macular choroidal thickness (SFCT), foveal no perfusion area (FAZ), superficial capillary density, deep capillary density, treatment effect, and adverse reactions were compared before and after treatment and between the two groups., Results: Before treatment and 1-mo post-treatment, there was no statistically significant difference in the estimated BCVA in both groups ( P > 0.05). BCVA decreased in the Compaq group 3 mo after treatment, and the difference was statistically significant ( P < 0.05). Before treatment, and 1 mo and 3 mo post-treatment, there was no statistically significant difference in the estimated IOP in either group ( P > 0.05). Before treatment and 1-mo post-treatment, there was no statistically significant difference in the estimated CMT, SFCT, or FAZ in either group ( P > 0.05). CMT and SFCT values decreased in the Compaq group 3 mo post-treatment, and the difference was statistically significant ( P < 0.05). Before treatment, and 1 mo and 3 mo post-treatment, there were no statistically significant differences in vascular density in the shallow or deep capillary plexi of the fovea, parafovea, or overall macular area between the two groups ( P > 0.05). Marked efficient, effective, and invalid rates were 70.83% and 52.08%, 27.08% and 39.58%, and 2.08% and 8.33% in the Compaq and ranibizumab groups, respectively. The differences between the two groups were statistically significant ( P < 0.05)., Conclusion: Anti-VEGF drugs can effectively improve CMT and SFCT, without affecting microcirculation, thus providing an effective and safe treatment for patients with DME., Competing Interests: Conflict-of-interest statement: All authors have nothing to disclose., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)

On 3 May 2002 the announcement finally arrived and signaled the end of all gossip and speculation. Hewlett-Packard CEO Carleton "Carly" Fiorina formally declared that HP had closed the $19 billion merger with Compaq Computer Corporation, thus creating a global powerhouse in the IT industry. According to HP, the merger would forge a "dynamic, powerful team" consisting of 140,000 employees with capabilities in 178 countries doing business in more than 40 currencies and ten languages. [ABSTRACT FROM AUTHOR]

Background: Acne confers an increased risk of physical, psychiatric, and psychosocial sequelae, potentially affecting multiple dimensions of health-related quality of life (HRQoL). Morbidity associated with truncal acne is poorly understood., Objective: To determine how severity and location of acne lesions impact the HRQoL of those who suffer from it., Methods: A total of 694 subjects with combined facial and truncal acne (F+T) and 615 with facial acne only (F) participated in an online, international survey. Participants self-graded the severity of their acne at different anatomical locations and completed the dermatology life quality index (DLQI)., Results: The F+T participants were twice as likely to report "very large" to "extremely large" impact on HRQoL (ie, DLQI > 10 and children's DLQI [CDLQI] > 12) as compared with the F participants (DLQI: odds ratio [OR] 1.61 [95% confidence interval {CI} 1.02-2.54]; CDLQI: OR 1.86 [95% CI 1.10-3.14]). The impact of acne on HRQoL increased with increasing acne severity on the face (DLQI and CDLQI P values = .001 and .017, respectively), chest ( P  = .003; P  = .008), and back ( P  = .001; P  = .028)., Limitations: Temporal evaluation of acne impact was not estimated., Conclusions: Facial and truncal acne was associated with a greater impact on HRQoL than facial acne alone. Increasing severity of truncal acne increases the adverse impact on HRQoL irrespective of the severity of facial acne., Competing Interests: Dr Tan has acted as a consultant for and/or received grants/honoraria from Bausch, 10.13039/501100009754Galderma, 10.13039/100004319Pfizer, Almirall, Boots/10.13039/100005153Walgreens, Botanix, Cipher, 10.13039/501100009754Galderma, Novan, 10.13039/100004336Novartis, Promius, 10.13039/501100004296Sun, Vichy. Dr Chavda is an employee of Galderma. Dr Beissert, Dr Cook-Bolden, Dr Harper, Dr Hebert, Dr Lain, Dr Layton, Dr Weiss, and Pr Dréno have acted as investigators and consultants for Galderma. Dr Rocha has acted as an advisor and/or speaker and received honoraria from Eucerin, Galderma, Johnson&Johnson and Leo Pharm., (© 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.)